) is the most common malignant brain tumor in childhood. It contains at least four distinct molecular subgroups. The aim of this study is to explore novel diagnostic and potential therapeutic markers within each subgroup of MB, in particular within Group 4, the largest subgroup, to facilitate diagnosis together with gene therapy. One hundred and six MB samples were examined.
| INTRODUCTION
Medulloblastoma (MB) is the most common malignant brain tumor in childhood. A multimodal treatment strategy, with surgical resection followed by radiotherapy and chemotherapy, has improved the overall 5 year-survival rate to >80%, but the prognosis for patients with recurrent MB remains very poor; patients with areas of frank dissemination had a low 5-year event-free survival rate of approximately 36%. 1, 2 There is now a consensus, based on current studies, including our recent results, that MB is not a single tumor, but is rather a heterogeneous group of tumors that differ not only in histologic appearance, but also in molecular biology. Medulloblastoma can be divided into at least four clinically, transcriptionally, and genetically distinct molecular variants. [3] [4] [5] These include the WNT and SHH groups of tumors, which show overexpression of regulators and target genes in the WNT and SHH signaling pathways, respectively, Group 3 tumors, in which most tumors show MYC amplification and the worst prognosis, and Group 4 tumors, which is the largest subgroup of MB. 4 Subgroup-specific markers to facilitate diagnosis together with precision gene therapy have thus become a critical area in next-generation clinical trials for MB.
Although Group 4 is the largest subtype of MB (up to 30% of tumors), 6 its molecular pathogenesis is the least well understood.
The genetic and epigenetic foundations of this group and their clinical significance is incompletely understood. [7] [8] [9] Our previous studies showed that MB is an epigenetic disease. 5, 10, 11 MicroRNA (miR)-449a was identified as a potential epigenetic marker of the Wnt subgroup. 5 However, so far, there are few adequately characterized group-specific epigenetic markers for Group 4.
Our aim was to integrate more potential subtype-specific biomarkers for each subgroup of MBs, especially for Group 4, into the NanoString platform to improve diagnosis efficiency and to find novel therapeutic targets for this tumor. Based on our preliminary result and the criteria in the new WHO classification on MB, 3, 5 the customdesigned CodeSet with 11 cancer-related genes and 22 well-characterized group-specific genes were included for the present study. Clinicopathologic information is summarized in Table 1 . This study was approved by the Institutional Review Board of Peking University (review reference no. IRB00001052-14003).
| MATERIALS AND METHODS

| Clinicopathologic information
| Candidate gene selection
Gene expression analysis was carried out using the classic MB subtyping gene CodeSet, which included 22 well known signature genes for different subgroups, 5, 12 as well as 11 additional tumor-related genes.
Six of the tumor-related genes (ALK, MYCN, TP53, GLI1, MYC, and SNCAIP) have been reported to be related with different subtypes of this malignant brain tumor, based on various technical assays, and were integrated into the CodeSet here to improve the efficiency of clinical molecular testing as well as strengthen the subtyping fidelity of the NanoString platform. 7, [13] [14] [15] [16] [17] [18] In addition, some candidates for therapeutic targets of this tumor, which were screened by our previous study (data not shown), were recruited in the current panel of genes, such as FGFR1, PDGFRA, and CCND1. [19] [20] [21] [22] [23] [24] The relationship between these genes and tumor subtyping need to be further elucidated. HNF4A, which was recently found to be a specific protein marker in exosomes from supernatant of an MB cell line, 25 as well as SNCA, which encodes a-synuclein, an interactive protein of synphilin-1, which is encoded by SNCAIP, 13 were also included in this study.
| RNA isolation and NanoString analysis
Total RNA from formalin-fixed, paraffin-embedded sections extracted from 75 MB samples were analyzed based on the NanoString nCounter Analysis System (NanoString Technologies, Seattle, WA, USA) in the Department of Pathology, Peking University Health Science Center (Beijing, China). All procedures related to mRNA quantification, including sample preparation, hybridization, detection, and scanning, were carried out as previously described. 5 RNA concentration was measured by Qubit (Thermo Fisher). All samples consisted of at least 80% of tumor cells. Normalization of the raw NanoString data was undertaken using nSolver Analysis Software version 2.5 (NanoString Technologies). 12 All statistical analyses were carried out with the R statistical programming environment (version 3.1.1). The Kruskal-Wallis test was used to correlate tumor type and gene expression. The experiment was repeated twice.
| Immunohistochemistry
Formalin-fixed, paraffin-embedded sections from 93 MB were reviewed. Immunohistochemistry (IHC) staining was carried out using a-synuclein primary mAb (1:1500; 610787; BD Biosciences, San Jose, CA, USA). Staining patterns of a-synuclein were assessed by two neuropathologists (QC and YFZ) independently, and results were merged to a consensus score. Briefly, the proportion of cells with strong asynuclein immunoreactive staining in the cell cytoplasm and/or nucleus in the total tumor area was estimated for each patient. 26 Absence of staining or weak staining was scored as zero. Red blood cells in tumor vessels served as the positive internal control.
| Demethylation treatment of MB cell lines
Three MB cell lines (Daoy, D283, and D341) obtained from the ATCC (Manassas, VA, USA) were treated with 5-aza-2 0 -deoxycytidine as previously reported, 27 and tested for restoration of SNCA gene expression with real-time PCR.
2.6 | Sodium bisulfite treatment of DNA followed by methylation-specific PCR and pyrosequencing for detection of SNCA promoter methylation in primary MB
Genomic DNA from MB cell lines were treated with sodium bisulfite using the BIsulFlash DNA Modification Kit (EpiGentek, Farmingdale, 
NY, USA) according to the manufacturer's recommendations. 27 The methylation status of SNCA promoter in MB cell lines and 51 primary MBs was evaluated with methylation-specific PCR (MSP) and pyrosequencing (PyroMark Q96; Qiagen, Hilden, Germany) analyses (Table S1) 
| Western blot assay to detect a-synuclein expression in MB cells
Western blot assay was carried out using a-synuclein primary mAb
(1:1000, 610787; BD Biosciences) to detect the a-synuclein (Table S1 ). and analyzed using a bright field microscope. All functional experiments were repeated three times. 
| Statistical analysis
All statistical analyses was undertaken using the SPSS 20.0 statistical software package. Results are presented as mean AE SEM. Student's t-test was used to determine statistical differences between subgroups. Analysis of variance was used to evaluate the relationship between SNCA expression and clinicopathologic characteristics.
Spearman's analysis was used to evaluate the correlation between RNA and protein levels of SNCA expression in MB tumors, as well as the consistency of SNCA and SNCAIP expression in these primary tumors. Other results were evaluated with the independent samples t-test. P-values <.05 were considered to be statistically significant.
| RESULTS
| Subgroup assignment of MB and novel
signature genes specific to each group identified by NanoString assay
Our previous study validated the reliability of the NanoString assay for MB subgrouping in 45 Chinese patients using the 22 classic gene CodeSet with the NanoString nCounter Analysis System (NanoString Technologies). 5 To further integrate more subgroup-specific genes recruited by the 2016 WHO classification and other studies using various techniques into one platform, and to find therapeutic targets in the current study, we assigned molecular subgroups in 72 primary Figure 1 ). Analysis and normalization of raw NanoString data using nSolver Analysis Software version 2.5 (NanoString Technologies) showed a "quantification control (QC) flag" in 3/75 (4%) of cases (MB25, MB26, and MB27), which means our current NanoString assay was unable to provide a high confidence for subgroup assignment in these three cases (Table S2) . are associated with the SHH group; MYC is associated with Group 3;
and SNCAIP and SNCA are associated with Group 4 (Figure 1 ).
| Receiver operating characteristic curves of 10 newly identified subtyping genes
To evaluate the accuracy of these 10 genes as diagnostic markers to discriminate different subgroup tumors, receiver operating character- on the RNA level was significantly higher than in WNT, SHH, and Group 3 (P < .0001; Figure 3 ), indicating that SNCA is a diagnostic marker with high sensitivity and specificity for subtyping MB on the RNA level.
| Alpha-synuclein expression and its association with MB subgroups
To illustrate protein expression of a-synuclein encoded by SNCA in MB, IHC staining was undertaken in 93 MBs, and showed cytoplasmic and/or nuclear staining in differing proportions of the tumor area (Table 1 ; Figure 4 ). Among these MBs, 59 cases have been detected by the NanoString platform and were assigned with molecular subgroups (Table 1) . The proportions of a-synuclein immunoreactivity in Group 4 was significantly higher compared with WNT and SHH groups (P = .0413 and.0381, respectively, t-test; Table 2 
MB3). No methylation was detected in Daoy cells or primary tumor (MB1). An unmethylated band was detected in all cell lines and primary tumors, including D283 and D341 cells, and in the hypermethylated tumor (MB3). No methylation was detected in normal cerebellar tissue (NC1).
(C) SNCA promoter CpG islands were analyzed by pyrosequencing. Higher frequency of methylation (≥5%) can be identified in three of six CpG sites in the promoter region of SNCA in MB3. However, the frequency of methylation of the other three CpG sites is low (<5%). No hypermethylation was detected in MB1. H 2 O, negative control; Uni, universal methylated DNA was used as positive control 27.62% AE 5.932%, n = 21) than that of Group 3 (with means of 19.44% AE 6.641%, n = 18), although the difference was not statistically significant in our cohort (P = .3632, t-test; Figure 3B ). The SNCA gene expression on RNA and protein levels showed significant correlation (P < .0001, R 2 = 0.3256; Table 2 , Figure 3C ). RNA expression of SNCA was also closely related with that of SNCAIP, based on our NanoString data (P < .0001; Figure S1 ). Both of these molecules are specific markers with relatively high expression level in Group 4 MBs (Figure 2 ). Figure 5C ), implying that epigenetic mechanisms other than DNA hypermethylation might play the key role in the regulation of SNCA expression (e.g. histone modification).
3.5 | Capacity for migration and invasion in MB cells after knockdown and overexpression of asynuclein, respectively
To explore the function of SNCA in MB cells, specific knockdown assays by siRNA transfection were carried out. Expression of SNCA was inhibited by siRNA ( Figure 6 ). After transfection, the invasion ability of MB was significantly increased compared with the negative control. In contrast, overexpression of SNCA can decrease the invasion ability ( Figure 7A ). Wound healing assays showed that the migration ability was also increased after transfection of SNCA siRNA ( Figure 7B ).
| Cell apoptotic and proliferation ability
To evaluate the effect of SNCA on apoptosis in MB cells, the Annexin V/PI detection assay was carried out (Figure 8) . The It is well known that increased expression of SNCA is closely correlated with increased risk of developing Parkinson's disease (PD). 32 Recently, it was reported that polymorphism in the SNCA gene is associated with PD phenotype. 33 Non-viral vectors that can deliver siRNA against SNCA has been developed and can prevent PD-like symptoms both in vitro and in vivo, 34 indicating that SNCA can be the potential target of gene therapy. Co-expression of a-synuclein and synphilin-1, which are encoded by SNCA and SNCAIP, respectively, favor the formation of Lewy bodies in the brain of patients with PD. 35, 36 Interestingly, the expression of a-synuclein could also be identified diffusely in tumors showing neuronal differentiation, including MB. 26, 37 Although the duplication of SNCAIP has been reported to be a somatic event highly specific to Group 4 MB, 13 so far the relationship between SNCA and MB subtype has not been clarified. Based on the present data from subtyping, our study then focused on the SNCA gene in the largest subgroup of MB.
The RNA expression level of SNCA in Group 4 detected in the current study was significantly higher than each of the other three subgroups, and the area under the ROC curve was rather high, F I G U R E 8 Quantification of apoptotic human medulloblastoma cells with and without SNCA overexpression was determined by the Annexin V-propidium iodide method. The percentages of cells that are in early and late stages of apoptosis or already dead are significantly higher in cells with SNCA overexpression than in those without gene overexpression. P < .0001. N-con, negative control F I G U R E 7 (A) Transwell invasion assay. Daoy cells after transfection of SNCA siRNA1, siRNA2, siRNA3, or GV219-SNCA-wt for 24 h. After knockdown transfection, the invasion ability of Daoy cells after transfection of SNCA siRNA was significantly increased compared with the negative siRNA control (N-con). After overexpression of SNCA, the invasion ability decreased significantly. HPF, high power field (940). (B) Wound healing assay. Daoy cells showed that the migration ability was significantly increased after transfection of SNCA siRNA for 24 h compared with N-con. Low power field (94). **P < .01; ****P < .0001; a-Syn, GV219-SNCA-wt vector transfection indicating SNCA is a diagnostic marker for Group 4 MB with high sensitivity and specificity on the mRNA level. In addition, Alpha-synuclein aggregation was recently identified as essential to apoptotic neurons in PD. 38 It was also observed to be downregulated by miR-153-3p and miR-205-5p in neuroblastoma cells, suggesting its potential as a tumor suppressor. 39 In the present study, the anti-apoptotic function and invasion ability of MB cells, rather than cell proliferation, were increased after SNCA siRNA transfection, but decreased after overexpression of the gene, indicating the potential tumor suppressor function of SNCA in MB. Expression of SNCA was observed to have a close relationship with SNCAIP in MB ( Figure S1 ), which has been reported to be related with various tumors. 40, 41 Future study will be required to understand the mechanism of the synergetic effect between SNCA and SNCAIP on MB tumor invasion as well as apoptosis in vitro and in vivo.
Recently, each subgroup of MB was split further based on comprehensive molecular profiling that can improve disease risk stratification and inform treatment decisions. 42, 43 In order to integrate more diagnostic markers and candidates for therapeutic targets of this tumor into one testing platform, we also investigated the correlation of several additional candidate signature genes with subgroups of MB. Some of these markers, such as ALK in the WNT group, TP53, NMYC, and GLI1 in the SHH group, MYC in Group 3, and SNCAIP in Group 4, have been identified in various studies using different methods, which strongly supports the results from the NanoString assay in the current study. 7, [13] [14] [15] [16] [17] [18] Furthermore, we identified several novel MB subgroup markers, including FGFR1 and PDGFRA in the WNT group and CCND1 in the SHH group. These three genes have all been reported to be potential targets for gene therapy in various tumors. [20] [21] [22] It is hoped that further exploration in vitro and in vivo will reveal their therapeutic value in specific subtypes of MB.
PDGFRA was assigned to the WNT group in the present cohort, whereas it has been classified to the SHH group in another report. 7 The inconsistency between different studies could be due to variations from different races or technique platforms, which need larger cohorts of samples to clarify.
In summary, we showed for the first time that SNCA is a Group 4-related diagnostic marker with both high sensitivity and specificity in MB. SNCA expression might be regulated indirectly with epigenetic mechanisms rather than DNA hypermethylation. Further survival analyses will clarify its prognostic value for MB patients. In addition, the NanoString gene expression assay enriched with the 33 custom-designed gene CodeSet showed excellent efficiency for MB subgroup assignment and potential biomarker identification. Our knowledge of MB in this study will shed new light on clinical usage of molecular subtyping of MB and, ultimately, benefit the patients.
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